DPP‐4 Inhibitor Linagliptin Attenuates A β‐induced Cytotoxicity through Activation of AMPK in Neuronal Cells
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: Aim: It is now clear that insulin signaling has important roles in regulation of neuronal functions in the brain. Dysregulation of brain insulin signaling has been linked to neurodegenerative disease, particularly Alzheimer's disease (AD). In this regard, there is evidence that improvement of neuronal insulin signaling has neuroprotective activity against amyloid β (A β)‐induced neurotoxicity for patients with AD. Linagliptin is an inhibitor of dipeptidylpeptidase‐4 (DPP‐4), which improves impaired insulin secretion and insulin downstream signaling in the in peripheral tissues. However, whether the protective effects of linagliptin involved in A β‐mediated neurotoxicity have not yet been investigated. Methods: In the present study, we evaluated the mechanisms by which linagliptin protects against A β‐induced impaired insulin signaling and cytotoxicity in cultured SK‐N‐MC human neuronal cells. Results: Our results showed that A β impairs insulin signaling and causes cell death. However, linagliptin significantly protected against A β‐induced cytotoxicity, and prevented the activation of glycogen synthase kinase 3 β (GSK 3 β) and tau hyperphosphorylation by restoring insulin downstream signaling. Furthermore, linagliptin alleviated A β‐induced mitochondrial dysfunction and intracellular ROS generation, which may be due to the activation of 5′ AMP‐activated protein kinase (AMPK)‐Sirt1 signaling. This upregulation of Sirt1 expression was also observed in diabetic patients with AD coadministration of linagliptin. Conclusions: Taken together, our findings suggest linagliptin can restore the impaired insulin signaling caused by A β in neuronal cells, suggesting DPP‐4 inhibitors may have therapeutic potential for reducing A β‐induced impairment of insulin signaling and neurotoxicity in AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“have firstly proposed a connection between increased insulin resistance in the brain with AD and termed it as “type 3 diabetes” [30], hinting that insulin-based therapies may be useful in the treatment of AD.”
BackgroundAblation of Insulin-Producing Neurons in Flies: Growth and Diabetic Phenotypes
Rulifson, E. J., Kim, S. K., & Nusse, R. (2002) · Science · doi:10.1126/science.1070058 · Cited by 1,064
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Vagelatos, N. T., & Eslick, G. D. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs012 · Cited by 320 · cited 1×
“Although the underlying mechanism remains largely unknown, now the evidence for it has become very significant [29].”
BackgroundInsulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236 · cited 1×
“It is well known that insulin and its receptors are widely expressed in neurons and glial cells throughout the brain [6], and evidence is also presented that insulin can be produced locally within the brain [7].”
BackgroundHamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration
Spielman, L. J., Little, J. P., & Klegeris, A. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.004 · Cited by 182 · cited 1×
“Particularly, defective brain insulin signaling has been implicated in the development of Alzheimer’s disease (AD), the most common cause of dementia [1].”
BackgroundHolscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102 · cited 1×
“Interestingly, it has been recently shown that incretins may be good candidates for treating AD [16].”
Background
Cited by
Insulin and Insulin Resistance in Alzheimer’s Disease
Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189987 · Cited by 377
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
AMPK activation: Role in the signaling pathways of neuroinflammation and neurodegeneration
Peixoto, C. A., Oliveira, W. H. D., Araújo, S. M. D. R., & Nunes, A. K. S. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.013 · Cited by 196
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“In vitro evidence identified that linagliptin, a DPP-IV inhibitor, reduces A β -mediated cytotoxicity and mitochondrial dysfunction, restoring impaired insulin signalling in cultured SK-N-MC human neuronal cells (Kornelius et al., 2015).”
Metadata
- Authors
- Kornelius, E., Lin, C., Chang, H., Li, H., Huang, W., Yang, Y., Lu, Y., Peng, C., & Huang, C.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2015-05-26
- Volume
- 21
- Issue
- 7
- Pages
- 549-557
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1549622883
- Cited by
- 123
- References
- 9
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.